866-997-4948(US-Canada Toll Free)

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 43 Pages

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2017

Summary

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) is a protein encoded by the TNFRSF6 gene. It acts as a receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. FAS-mediated apoptosis plays an important role in the induction of peripheral tolerance in the antigen-stimulated suicide of mature T-cells.

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Ophthalmology, Central Nervous System, Dermatology, Gastrointestinal and Infectious Disease which include indications Autoimmune Disorders, Retinal Pigment Epithelial (RPE) Detachment, Actinic (Solar) Keratosis, Chronic Lymphocytic Leukemia (CLL), Dry (Atrophic) Macular Degeneration, Genital Warts (Condylomata Acuminata), Liver Cancer, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Lymphoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Solid Tumor, Transplant Rejection, Warts and Wet (Neovascular / Exudative) Macular Degeneration.

The latest report Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Overview 6
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Assessment 13
Assessment by Mechanism of Action 13
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Companies Involved in Therapeutics Development 19
Baliopharm AG 19
G&E Herbal Biotechnology Co Ltd 19
KAHR medical Ltd 20
Silence Therapeutics Plc 20
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Drug Profiles 21
Antisense RNAi Oligonucleotide to Inhibit FAS for Liver Diseases - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
APO-010 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
KAHR-102 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Novotarg - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ONL-101 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
ONL-1204 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
SRT-100 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Dormant Products 32
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Product Development Milestones 33
Featured News & Press Releases 33
May 31, 2017: MPI's spinout Oncology Venture's second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug 33
May 31, 2017: OVs second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug 33
Mar 28, 2017: ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team 33
Mar 21, 2017: ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program 35
Oct 07, 2016: All four Danish centers have started screening Multiple Myeloma patients for OVs APO010 Study 35
Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OVs APO010 Study 36
Mar 10, 2016: First Patient Included In APO010 Immuno-Oncology Screening Trial By MPI's Spinout Oncology Venture 36
Feb 11, 2016: ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment From FDA 37
Jun 15, 2015: ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases 38
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA 39
Dec 16, 2014: KAHR Medical receives government grant sum of 8.2 M Shekels approved by the Chief Scientist Office 39
Nov 12, 2014: ONL Therapeutics Receives Phase II SBIR Grant From National Eye Institute for Development of Novel Retinal Disease Treatment 39
Dec 24, 2013: KAHR Medical to Receive NIS 4 million (over $1.1 million USD) in Additional Government Grants 40
Mar 06, 2013: Silence Reports Results From Proof-of-concept Studies In Acute Liver Injury 40
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Baliopharm AG, H2 2017 19
Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017 19
Pipeline by KAHR medical Ltd, H2 2017 20
Pipeline by Silence Therapeutics Plc, H2 2017 20
Dormant Projects, H2 2017 32

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Routes of Administration, H2 2017 15
Number of Products by Stage and Routes of Administration, H2 2017 15
Number of Products by Molecule Types, H2 2017 17
Number of Products by Stage and Molecule Types, H2 2017 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *